INTRODUCTION
Endocrine and metabolic disorders involve abnormalities in hormone and metabolic processes, including conditions such as thyroid diseases and diabetes. These disorders not only disrupt patients' metabolic balance but may also lead to multiple complications.
The Boji Pharmaceutical project team maintains strong relationships with domestic endocrinology experts and has managed clinical research projects involving clamp studies, insulin, DPP-4 inhibitors, metformin, and similar compounds. The team possesses experience in passing on-site inspections for comparable projects.
In 2024, the company signed a Technical Service (Commissioned) Contract with Notai Biotech for clinical research services related to “Semaglutide Injection.” The total contract value is RMB 108 million. Currently, trials for both weight reduction and blood glucose control indications have progressed to the confirmatory clinical phase, with both receiving ethics approval from the lead institution in August 2024. This project demonstrates industry recognition of Boji's operational capabilities in endocrine and metabolic disease research, further strengthening the company's R&D capabilities in this therapeutic area.
Clinical Research Project Experience
- Diabetes
- Weight loss
PROJECT EXPERIENCE

Assisted in the successful approval and market launch of China's first Class 1.1 innovative traditional Chinese medicine for treating gout.
Hu Zhen Qing Feng Capsules, China's first Class 1.1 TCM innovation drug for treating gout, represents the highest level of pharmaceutical innovation within China's drug registration classification system. Class 1.1 new drugs exhibit exceptionally high innovation and significant market scarcity.
Leveraging its unique strengths in TCM R&D, extensive experience, and specialized team, Boji Pharmaceutical provided scientific and rigorous management services for the clinical trials of the Hu Zhen Qing Feng Capsules project, ensuring their successful execution.